A study of the effects of sumatriptan on myocardial perfusion in healthy female migraineurs using (NH3)-N-13 positron emission tomography

被引:32
作者
Lewis, PJ
Barrington, SF
Marsden, PK
Maisey, MN
Lewis, LD
机构
[1] GUYS & ST THOMAS HOSP, CLIN PET CTR, LONDON SE1 9RT, ENGLAND
[2] GUYS & ST THOMAS HOSP, DEPT NUCL MED, LONDON SE1 9RT, ENGLAND
[3] LEWISHAM HOSP, GUYS DRUG RES UNIT, LONDON SE13 6LH, ENGLAND
[4] LEWISHAM HOSP, DEPT MED, LONDON SE13 6LH, ENGLAND
关键词
D O I
10.1212/WNL.48.6.1542
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Sumatriptan, a 5-HT1D receptor agonist, is believed to alleviate migraine attacks by extracerebral vasoconstriction. Chest pain associated with myocardial ischemia may occur after sumatriptan administration. We investigated the effect of a single 6-mg subcutaneous dose of sumatriptan on myocardial perfusion (MP) as measured by (NH3)-N-13 positron emission tomography (PET) in a randomized double-blind, placebo-controlled, crossover trial at the Clinical PET Centre, Guy's and St. Thomas' Hospitals, London. Nineteen volunteer female migraineurs, age range 33 to 62 years, at low risk for ischemic heart disease were included. All had undergone previous treatment with oral or intravenous sumatriptan. Patients were recruited by advertisement and referral from local neurology specialists. Each volunteer underwent two scanning sessions. On each occasion, a baseline dynamic (NH3)-N-13 PET scan was acquired followed by a (NH3)-N-13, PET scan 10 minutes after subcutaneous injection of placebo or 6 mg of sumatriptan. Regional MP was measured in five myocardial regions using the Patlak system of image analysis. The mean % change from baseline (+/-SD) in global MP after placebo was +9.5% +/- 18.0 and after sumatriptan was +6.6% +/- 18.8 (repeated measures ANOVA for treatment effect p = 0.56). There were no significant differences in MP changes from baseline observed in any of the five myocardial regions (treatment p = 0.32 to 0.84). These data suggest that in healthy female migraineurs, a single 6-mg subcutaneous dose of sumatriptan does not cause a significant change in regional or global myocardial perfusion.
引用
收藏
页码:1542 / 1550
页数:9
相关论文
共 29 条
[1]   DETERMINATION OF SUMATRIPTAN SUCCINATE IN PLASMA AND URINE BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH ELECTROCHEMICAL DETECTION [J].
ANDREW, PD ;
BIRCH, HL ;
PHILLPOT, DA .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1993, 82 (01) :73-76
[2]   CORONARY VASOSPASM AND SUMATRIPTAN - REPLY [J].
ARMITAGE, M ;
CURZEN, N ;
WILLETT, F .
BRITISH MEDICAL JOURNAL, 1992, 305 (6845) :118-118
[3]   5-HT RECEPTORS MEDIATING CONTRACTIONS OF THE ISOLATED HUMAN CORONARY-ARTERY [J].
BAX, WA ;
RENZENBRINK, GJ ;
VANHEUVENNOLSEN, D ;
THIJSSEN, EJM ;
BOS, E ;
SAXENA, PR .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1993, 239 (1-3) :203-210
[4]   THE SAFETY AND TOLERABILITY OF SUMATRIPTAN - AN OVERVIEW [J].
BROWN, EG ;
ENDERSBY, CA ;
SMITH, RN ;
TALBOT, JCC .
EUROPEAN NEUROLOGY, 1991, 31 (05) :339-344
[5]   TREATMENT OF ACUTE MIGRAINE WITH SUBCUTANEOUS SUMATRIPTAN [J].
CADY, RK ;
WENDT, JK ;
KIRCHNER, JR ;
SARGENT, JD ;
ROTHROCK, JF ;
SKAGGS, H .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 265 (21) :2831-2835
[6]  
CHOI Y, 1993, J NUCL MED, V34, P488
[7]   5-HYDROXYTRYPTAMINE CONTRACTS HUMAN CORONARY-ARTERIES PREDOMINANTLY VIA 5-HT2 RECEPTOR ACTIVATION [J].
CONNOR, HE ;
FENIUK, W ;
HUMPHREY, PPA .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1989, 161 (01) :91-94
[8]  
CUSHING DJ, 1992, J PHARMACOL EXP THER, V263, P123
[9]  
FERRARI MD, 1991, NEW ENGL J MED, V325, P316
[10]   THE CLINICAL-PHARMACOLOGY, PHARMACOKINETICS AND METABOLISM OF SUMATRIPTAN [J].
FOWLER, PA ;
LACEY, LF ;
THOMAS, M ;
KEENE, ON ;
TANNER, RJN ;
BABER, NS .
EUROPEAN NEUROLOGY, 1991, 31 (05) :291-294